Everyone's favorite Neop short Marty posted an opinion on SA that Lymphoseek could not be approved because the trial was run against blue dye and not the (unapproved) SOC of blue dye and SC. He even filed a silly citizen's petition based on it. Now this Pharmalucence gets approval for SC after they put it up against blue dye as well.
Regardless of one's opinion of the commercial viability and/or market share of Lymphoseek, or the valuation of Neop's pps, does this SC approval basically negate Marty's thesis?
News 
Market Data 
Discover 
AI
